Ception Therapeutics

Company: Ception Therapeutics

Financing: $77M
Website: http://www.ceptiontx.com/

After gaining an impressive $63 million in the first tranche of its third round in January, Malvern, PA-based Ception upped the ante by gaining an additional $14.7 in its second tranche in May, bringing the grand total to $77 million in its third round. Participants included Essex Woodlands Health Ventures, Third Point and Greenlight Capital. Ception’s pipeline includes a late-stage biologic agent in clinical development for multiple inflammatory conditions, a small molecule anti-TNF program and other discovery programs. The company plans to use the money to advance its lead compound as well as support development of earlier-stage drug targets.

Related Article:
Ception Therapeutics pockets $63M in third round. Report


Ception Therapeutics

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.